Trial Profile

A Phase 1 Open-Label, Multi-Center Study of PSMA Targeted Genetically Modified Chimeric Antigen Receptor T Cells in Patients With Metastatic Castration Resistant Prostate Cancer

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 23 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PSMA specific TGF beta resistant CAR T cell therapy Tmunity Therapeutics (Primary) ; Anakinra; Cyclophosphamide; Fludarabine
Indications Prostate cancer
Focus Adverse reactions
Acronyms CART-PSMA-02
Sponsors Tceleron Therapeutics; Tmunity Therapeutics

Most Recent Events

11 Apr 2023 Status changed from active, no longer recruiting to discontinued.
19 Feb 2022 Results (n=9; As of October 2021) presented at the 2022 Genitourinary Cancers Symposium
08 Jun 2021 Results (As of January 2021, N=6) presented at the 57th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com